Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance
Details
Publication Year 2024-06,Volume 54,Issue #6,Page 1017-1030
Journal Title
Internal Medicine Journal
Publication Type
Guideline
Abstract
Marginal zone lymphomas (MZLs) are a rare, indolent group of non-Hodgkin lymphomas with different diagnostic, genetic and clinical features and therapeutic implications. The most common is extranodal MZL of mucosa-associated lymphoid tissue, followed by splenic MZL and nodal MZL. Patients with MZL generally have good outcomes with long survival rates but frequently have a relapsing/remitting course requiring several lines of therapy. The heterogeneous presentation and relapsing course present the clinician with several diagnostic and therapeutic challenges. This position statement presents evidence-based recommendations in the setting of Australia and New Zealand.
Publisher
Wiley
Keywords
Humans; Australia; Consensus; *Lymphoma, B-Cell, Marginal Zone/diagnosis/therapy; New Zealand; Australasian Lymphoma Alliance; marginal zone lymphoma; practice statement; treatment
Department(s)
Clinical Haematology; Familial Cancer Centre; Radiation Oncology
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-08-06 05:29:17
Last Modified: 2024-08-06 05:31:19

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙